The combination of atezolizumab and bevacizumab was evaluated in two clinical studies of patients with advanced RCC in which immune markers were correlated with clinical efficacy to investigate the mechanisms underpinning PD-L1/VEGF inhibition (98, 99). This evidence concerns the gene CD274 and renal cell carcinoma.